tumour
Conditions
Interventions
Observation group:N/A
Sponsors
Mianyang Central Hospital/Mianyang Hospital Affiliated to Medical School of University of Electronic Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ?18 years old and above ? Solid malignant tumors were diagnosed by histopathology ? ECOG PS score 0-2 ? Systemic therapy includes chemotherapy, targeted therapy, immune surveillance point inhibitors, etc ? The expected survival time was more than 12 weeks
Exclusion criteria
Exclusion criteria: ? Patients had no hematological and imaging data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in peripheral blood lymphocyte count and immune markers; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) (proportion of patients with irCR and irPR) ;PFS: defined as the time from the start of treatment to tumor progression or death from any cause. Patient survival OS (time to death from any cause since the start of treatment);Toxicity reaction(Symptom scale); | — |
Countries
China
Contacts
Public Contactfeng Gao
Mianyang Central Hospital/Mianyang Hospital Affiliated to Medical School of University of Electronic Science and Technology of China
Outcome results
None listed